Literature DB >> 22252808

Case-control study comparing de novo and daptomycin-exposed daptomycin-nonsusceptible Enterococcus infections.

Theodoros Kelesidis1, Angela L P Chow, Romney Humphries, Daniel Z Uslan, David Pegues.   

Abstract

Understanding factors associated with de novo daptomycin-nonsusceptible Enterococcus (DNSE) infections will aid in better understanding the mechanisms of daptomycin nonsusceptibility. We conducted a case-control study to compare patients with DNSE infections who were daptomycin treatment naïve (n = 9) and those with DNSE infections who had exposure to daptomycin (n = 13). Less frequent exposure to antimicrobials, increased susceptibility to nitrofurantoin and gentamicin, and shorter duration of hospitalization were associated with de novo DNSE infection, suggesting a potential community reservoir.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252808      PMCID: PMC3318388          DOI: 10.1128/AAC.05918-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  7 in total

1.  Inhibition of vancomycin-resistant enterococcus by continuous-flow cultures of human stool microflora with and without anaerobic gas supplementation.

Authors:  Michael E Hume; Toni L Poole; Nicole J Pultz; Jennifer A Hanrahan; Curtis J Donskey
Journal:  Curr Microbiol       Date:  2004-05       Impact factor: 2.188

2.  Assessment of two commercial susceptibility test methods for determination of daptomycin MICs.

Authors:  James H Jorgensen; Sharon A Crawford
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

3.  Comparison of three PCR primer sets for identification of vanB gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by vanB-containing anaerobic bacilli.

Authors:  S A Ballard; E A Grabsch; P D R Johnson; M L Grayson
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Propagation of anaerobic bacteria within an aerobic multi-species chronic wound biofilm model.

Authors:  Y Sun; E Smith; R Wolcott; S E Dowd
Journal:  J Wound Care       Date:  2009-10       Impact factor: 2.072

5.  In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerrin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

Authors:  Theodoros Kelesidis; Romney Humphries; Daniel Z Uslan; David A Pegues
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 20.999

7.  Comment on: Successful therapy of treatment-emergent, non-clonal daptomycin-non-susceptible Enterococcus faecium infections.

Authors:  Theodoros Kelesidis
Journal:  J Antimicrob Chemother       Date:  2011-11-02       Impact factor: 5.758

  7 in total
  13 in total

Review 1.  Mechanisms of drug resistance: daptomycin resistance.

Authors:  Truc T Tran; Jose M Munita; Cesar A Arias
Journal:  Ann N Y Acad Sci       Date:  2015-10-23       Impact factor: 5.691

2.  Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.

Authors:  Ashley D Hall Snyder; Brian J Werth; Poochit Nonejuie; John P McRoberts; Joe Pogliano; George Sakoulas; Juwon Yim; Nivedita Singh; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.

Authors:  Janet A Hindler; Annie Wong-Beringer; Carmen L Charlton; Shelley A Miller; Theodoros Kelesidis; Marissa Carvalho; George Sakoulas; Poochit Nonejuie; Joseph Pogliano; Victor Nizet; Romney Humphries
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

Review 4.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

5.  Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors.

Authors:  A Chow; N N Win; P Y Ng; W Lee; M K Win
Journal:  Epidemiol Infect       Date:  2016-05-13       Impact factor: 4.434

6.  Frequency of susceptibility testing for patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Carmen L Giltner; Theodoros Kelesidis; Janet A Hindler; April M Bobenchik; Romney M Humphries
Journal:  J Clin Microbiol       Date:  2013-10-23       Impact factor: 11.677

7.  Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium.

Authors:  Romney M Humphries; Theodoros Kelesidis; Ryan Tewhey; Warren E Rose; Nicholas Schork; Victor Nizet; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.938

8.  Emergence of daptomycin-non-susceptible enterococci urinary tract isolates.

Authors:  Theodoros Kelesidis; Romney Humphries; Angela L P Chow; Sotirios Tsiodras; Daniel Z Uslan
Journal:  J Med Microbiol       Date:  2013-04-18       Impact factor: 3.196

9.  Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus.

Authors:  Jeremy C Storm; Daniel J Diekema; Jennifer S Kroeger; Sarah J Johnson; Birgir Johannsson
Journal:  Antimicrob Resist Infect Control       Date:  2012-05-29       Impact factor: 4.887

Review 10.  The zoonotic potential of daptomycin non-susceptible enterococci.

Authors:  T Kelesidis
Journal:  Zoonoses Public Health       Date:  2013-11-26       Impact factor: 2.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.